BRPI0809715A2 - "composto, método de tratamento de um distúrbio relacionado com a angiogênese,método de inibição da atividade de receptor de domínio de inserto de quinase, método de inibição de angiogênese e método de tratamento de degeneração macular" - Google Patents

"composto, método de tratamento de um distúrbio relacionado com a angiogênese,método de inibição da atividade de receptor de domínio de inserto de quinase, método de inibição de angiogênese e método de tratamento de degeneração macular" Download PDF

Info

Publication number
BRPI0809715A2
BRPI0809715A2 BRPI0809715-1A BRPI0809715A BRPI0809715A2 BR PI0809715 A2 BRPI0809715 A2 BR PI0809715A2 BR PI0809715 A BRPI0809715 A BR PI0809715A BR PI0809715 A2 BRPI0809715 A2 BR PI0809715A2
Authority
BR
Brazil
Prior art keywords
treating
angiogenesis
compound
macular degeneration
related disorder
Prior art date
Application number
BRPI0809715-1A
Other languages
English (en)
Inventor
Jia Hong
Duan Jifeng
Su Wei-Guo
Zhang Weihan
Yan Xiaoqiang
Sai Yang
Ren Yongxin
Cui Yumin
Original Assignee
Hutchison Medipharma Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Entpr Ltd filed Critical Hutchison Medipharma Entpr Ltd
Publication of BRPI0809715A2 publication Critical patent/BRPI0809715A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

derivados de pirimidina trata-se de compostos de pirimidina da fórmula (i) mostrados no relatório descritivo. também é apresentado um método de tratamento de um distúrbio relacionado com a angiogênese, por exemplo, câncer ou degeneração macular relacionada com a idade, com tal composto .
BRPI0809715-1A 2007-04-16 2008-04-15 "composto, método de tratamento de um distúrbio relacionado com a angiogênese,método de inibição da atividade de receptor de domínio de inserto de quinase, método de inibição de angiogênese e método de tratamento de degeneração macular" BRPI0809715A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91192107P 2007-04-16 2007-04-16
PCT/US2008/060366 WO2008128231A1 (en) 2007-04-16 2008-04-15 Pyrimidine derivatives

Publications (1)

Publication Number Publication Date
BRPI0809715A2 true BRPI0809715A2 (pt) 2019-11-05

Family

ID=39854302

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0809715-1A BRPI0809715A2 (pt) 2007-04-16 2008-04-15 "composto, método de tratamento de um distúrbio relacionado com a angiogênese,método de inibição da atividade de receptor de domínio de inserto de quinase, método de inibição de angiogênese e método de tratamento de degeneração macular"

Country Status (17)

Country Link
US (2) US8349859B2 (pt)
EP (1) EP2154967B9 (pt)
JP (1) JP5635398B2 (pt)
KR (1) KR101424847B1 (pt)
BR (1) BRPI0809715A2 (pt)
CA (1) CA2684470C (pt)
DK (1) DK2154967T5 (pt)
ES (1) ES2465673T3 (pt)
HR (1) HRP20140377T2 (pt)
MX (1) MX2009011199A (pt)
NZ (1) NZ580671A (pt)
PL (1) PL2154967T3 (pt)
PT (1) PT2154967E (pt)
RU (1) RU2455994C2 (pt)
SI (1) SI2154967T1 (pt)
TW (1) TWI484960B (pt)
WO (1) WO2008128231A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
TWI491605B (zh) * 2008-11-24 2015-07-11 Boehringer Ingelheim Int 新穎化合物
AR074209A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina utiles para el tratamiento del cancer
JP2012197231A (ja) * 2009-08-06 2012-10-18 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体
US8466155B2 (en) * 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
CN102070618B (zh) 2009-11-23 2013-08-21 和记黄埔医药（上海）有限公司 一种化合物及其晶体
EP2395001A1 (en) 2010-05-21 2011-12-14 Chemilia AB Novel pyrimidine derivatives
KR20130031296A (ko) 2010-05-21 2013-03-28 케밀리아 에이비 신규한 피리미딘 유도체
EP2433636A1 (en) * 2010-09-27 2012-03-28 Medizinische Universität Wien Treatment of Malignant Diseases
EP2621276B1 (en) * 2010-09-30 2017-12-27 Merck Sharp & Dohme Corp. 2-alkoxy pyrimidine pde10 inhibitors
EP2502924A1 (en) 2011-03-24 2012-09-26 Chemilia AB Novel pyrimidine derivatives
DK2688883T3 (en) 2011-03-24 2016-09-05 Noviga Res Ab pyrimidine
WO2013054351A1 (en) * 2011-08-08 2013-04-18 Cadila Healthcare Limited Heterocyclic compounds
EP2711365A1 (en) 2012-09-21 2014-03-26 Chemilia AB 4-Indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
EP2711364A1 (en) 2012-09-21 2014-03-26 Chemilia AB 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
CN104955459B (zh) 2012-11-05 2019-02-01 南特知识产权控股有限责任公司 取代的吲哚-5-酚衍生物及其治疗应用
CA2906185A1 (en) 2013-03-15 2014-09-18 Nantbioscience, Inc. Substituted indol-5-ol derivatives and their therapeutic applications
CN105601573B (zh) * 2014-11-24 2021-07-02 中国科学院上海药物研究所 2-氨基嘧啶类化合物及其药物组合物和应用
WO2016137506A1 (en) * 2015-02-27 2016-09-01 Nantbioscience, Inc. Pyrimidine derivatives as kinase inhibitors and their therapeutical applications
US10981899B2 (en) 2016-04-28 2021-04-20 Cornell University Inhibitors of soluble adenylyl cyclase
WO2020253862A1 (zh) * 2019-06-21 2020-12-24 上海翰森生物医药科技有限公司 含氮芳基磷氧化物类衍生物、其制备方法和应用
CN111004221B (zh) * 2019-12-13 2021-02-02 长治学院 一种嘧啶/苯并咪唑杂合物、制备方法及医药用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
HRP970371A2 (en) * 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
US6235741B1 (en) * 1997-05-30 2001-05-22 Merck & Co., Inc. Angiogenesis inhibitors
KR100838617B1 (ko) 1999-02-10 2008-06-16 아스트라제네카 아베 혈관형성 억제제로서의 퀴나졸린 유도체
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB9924862D0 (en) * 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
US6943161B2 (en) * 1999-12-28 2005-09-13 Pharmacopela Drug Discovery, Inc. Pyrimidine and triazine kinase inhibitors
HUP0301117A3 (en) * 2000-02-17 2004-01-28 Amgen Inc Thousand Oaks Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
WO2002016348A1 (en) * 2000-08-09 2002-02-28 Astrazeneca Ab Antiangiogenic bicyclic derivatives
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
MXPA03005696A (es) * 2000-12-21 2003-10-06 Glaxo Group Ltd Pirimidinaminas como moduladores de angiogenesis.
US20040092750A1 (en) * 2001-03-01 2004-05-13 Tomoyuki Hasegawa 2-methylindole-4-acetic acid, process for producing the same, and process for producing intermediate therefor
US20040171630A1 (en) * 2001-06-19 2004-09-02 Yuntae Kim Tyrosine kinase inhibitors
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
JP2005524668A (ja) 2002-03-01 2005-08-18 スミスクライン ビーチャム コーポレーション ジアミノピリミジン類及びそれらの血管新生阻害薬としての使用
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
US20060252943A1 (en) 2002-06-17 2006-11-09 Amogh Boloor Chemical process
ATE451104T1 (de) * 2002-07-29 2009-12-15 Rigel Pharmaceuticals Inc Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen
CA2488739A1 (en) * 2002-08-30 2004-03-11 Eisai Co., Ltd. Nitrogen-containing aromatic derivatives
WO2004032882A2 (en) 2002-10-10 2004-04-22 Smithkline Beecham Corporation Chemical compounds
EA200500721A1 (ru) 2002-11-28 2005-12-29 Шеринг Акциенгезельшафт Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
US7531553B2 (en) 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
US8084457B2 (en) * 2003-09-15 2011-12-27 Lead Discovery Center Gmbh Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
CN100584832C (zh) * 2003-09-18 2010-01-27 诺瓦提斯公司 可用于治疗增殖性病症的2,4-二(苯基氨基)嘧啶类
CA2545711A1 (en) * 2003-11-13 2005-06-02 Ambit Biosciences Corporation Urea derivatives as kinase modulators
US7718697B2 (en) 2003-12-17 2010-05-18 Alcon, Inc. Method for treating glaucoma comprising administering α-lipoic acid
MXPA06007242A (es) 2003-12-23 2006-08-18 Pfizer Nuevos derivados de quinolina.
DE102004044556A1 (de) * 2004-09-15 2006-03-30 Bayer Healthcare Ag Behandlung viraler Infektionen durch selektive Zerstörung virusinfizierter Zellen mit Stresskinase-Inhibitoren
TW200628463A (en) * 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp Heteroaryl compounds
CA2587590A1 (en) * 2004-11-19 2006-06-08 Synta Pharmaceuticals Corp. Pyrimidine compounds and uses thereof
WO2006071079A1 (en) 2004-12-29 2006-07-06 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
US20060247263A1 (en) * 2005-04-19 2006-11-02 Amgen Inc. Substituted heterocyclic compounds and methods of use
JP2008540436A (ja) * 2005-05-03 2008-11-20 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｊａｋキナーゼインヒビターおよびそれらの使用
EP1890703B1 (en) 2005-06-14 2016-05-11 Taigen Biotechnology Pyrimidine compounds as chemokine receptors inhibitors
US20090149467A1 (en) * 2005-09-15 2009-06-11 Merck & Co., Inc. Tyrosine Kinase Inhibitors

Also Published As

Publication number Publication date
TW200848049A (en) 2008-12-16
HRP20140377T1 (en) 2014-05-23
PL2154967T3 (pl) 2014-08-29
JP5635398B2 (ja) 2014-12-03
EP2154967B9 (en) 2014-07-23
EP2154967A4 (en) 2010-05-19
CA2684470A1 (en) 2008-10-23
NZ580671A (en) 2012-03-30
EP2154967B1 (en) 2014-03-05
WO2008128231A1 (en) 2008-10-23
US20080255172A1 (en) 2008-10-16
US20130065890A1 (en) 2013-03-14
EP2154967A1 (en) 2010-02-24
ES2465673T9 (es) 2014-11-14
AU2008240084A1 (en) 2008-10-23
RU2009141982A (ru) 2011-05-27
SI2154967T1 (sl) 2014-06-30
KR101424847B1 (ko) 2016-07-08
US8349859B2 (en) 2013-01-08
CA2684470C (en) 2016-02-09
MX2009011199A (es) 2010-03-17
US8901143B2 (en) 2014-12-02
TWI484960B (zh) 2015-05-21
DK2154967T5 (en) 2014-11-17
DK2154967T3 (da) 2014-04-07
JP2010524952A (ja) 2010-07-22
PT2154967E (pt) 2014-06-05
KR20100016592A (ko) 2010-02-12
HRP20140377T2 (hr) 2015-01-16
ES2465673T3 (es) 2014-06-06
RU2455994C2 (ru) 2012-07-20

Similar Documents

Publication Publication Date Title
BRPI0809715A2 (pt) "composto, método de tratamento de um distúrbio relacionado com a angiogênese,método de inibição da atividade de receptor de domínio de inserto de quinase, método de inibição de angiogênese e método de tratamento de degeneração macular"
GB0309009D0 (en) Quinazoline derivatives
TW200833686A (en) Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
TW200720268A (en) 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors
WO2007087245A3 (en) Ret tyrosine kinase inhibition
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
NO20083923L (no) Pyrazolkinoloner er potente parp-inhibitorer
UA100846C2 (uk) Сполуки та композиція як інгібітори протеїнкінази
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
BRPI0714665A2 (pt) Composto, pró-droga, agente farmacêutico, e, método para a profilaxia ou tratamento do câncer
TN2011000220A1 (en) Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
MX2009007075A (es) Metodos de uso para analogos de ciclopamina.
WO2009126514A8 (en) Compounds and compositions as kinase inhibitors
WO2007142905A3 (en) 1-sulfonylindazolylamine and -amide derivatives as 5-hydroxytryptamine-6 ligands
MX2010002899A (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de la histamina-3.
MX2009008386A (es) Derivados de 2-amino-5,7-dihidro-6h-pirrolo[3,4-d] pirimidina como inhibidores de proteinas de choque termico-90 para tratar cancer.
ATE438641T1 (de) Chinazolinderivate als inhibitoren von egf und/oder erbb2-rezeptortyrosinkinase
ECSP099046A (es) Derivados ciclopropil amina
ATE435223T1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate
EA200870454A1 (ru) Способ ингибирования c-kit киназы
HK1114385A1 (en) Quinazoline derivatives as egf and/or erbb2 tyrosine kinase inhibitors
TW200740766A (en) Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6-ligands
MX2008002158A (es) Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6.
HK1112462A1 (en) Pyrazolopyrimidine compounds as antitumor agents
TW200745090A (en) Chemical compounds

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A01N 43/54 , C07D 239/42

Ipc: C07D 403/14 (2006.01), C07D 401/14 (2006.01), C07D

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]